GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

In addition to this performance, GSK plc (NYSE:GSK) has 5 new products in the pipeline for which it expects approval in 2025. The company has also raised its 2031 sales outlook to more than £40 ...

A company's earnings performance is important for value investors as well. For fiscal 2025, five analysts revised their earnings estimate higher in the last 60 days for GSK, while the Zacks Consensus ...